{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:48Z","timestamp":1754162088137,"version":"3.41.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,29]]},"DOI":"10.7759\/cureus.88997","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:36:38Z","timestamp":1753814198000},"source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Latent Hepatitis B Infection on Autoimmune Hepatitis Treatment Outcomes"],"prefix":"10.7759","author":[{"given":"Sami","family":"Bahcebas\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuh Mehmet","family":"B\u00fcy\u00fckberber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori L","year":"2023","unstructured":"Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ. 2023, 380:e070201. 10.1136\/bmj-2022-070201","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001437","article-title":"Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients","volume":"31","author":"Yuan X","year":"2019","unstructured":"Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol. 2019, 31:1467-74. 10.1097\/MEG.0000000000001437","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.114985","article-title":"Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection","volume":"96","author":"Caviglia GP","year":"2020","unstructured":"Caviglia GP, Olivero A, Ciancio A, et al.. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn Microbiol Infect Dis. 2020, 96:114985. 10.1016\/j.diagmicrobio.2020.114985","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref4","article-title":"Assessment of latent infections in patients receiving biological therapies","volume":"32","author":"Fern\u00e1ndez-Ruiz M","year":"2019","unstructured":"Fern\u00e1ndez-Ruiz M. Assessment of latent infections in patients receiving biological therapies. Rev Esp Quimioter. 2019, 32:63-8.","journal-title":"Rev Esp Quimioter"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01983-5","article-title":"May previous hepatitis B virus infection be involved in etiology and pathogenesis of autoimmune liver diseases?","volume":"39","author":"Batskikh S","year":"2022","unstructured":"Batskikh S, Morozov S, Vinnitskaya E, et al.. May previous hepatitis B virus infection be involved in etiology and pathogenesis of autoimmune liver diseases?. Adv Ther. 2022, 39:430-40. 10.1007\/s12325-021-01983-5","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01851.x","article-title":"Occult hepatitis B virus infection in patients with autoimmune liver diseases","volume":"29","author":"Georgiadou SP","year":"2009","unstructured":"Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int. 2009, 29:434-42. 10.1111\/j.1478-3231.2008.01851.x","journal-title":"Liver Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2019.04.009","article-title":"Occult HBV infection in patients with autoimmune hepatitis: a virological and clinical study","volume":"53","author":"Chen XX","year":"2020","unstructured":"Chen XX, Xiang KH, Zhang HP, et al.. Occult HBV infection in patients with autoimmune hepatitis: a virological and clinical study. J Microbiol Immunol Infect. 2020, 53:946-54. 10.1016\/j.jmii.2019.04.009","journal-title":"J Microbiol Immunol Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2020.21.9.2555","article-title":"Frequency of OBI among patients with autoimmune hepatitis","volume":"21","author":"Hayat Davoudi G","year":"2020","unstructured":"Hayat Davoudi G, Makvandi M, Teimoori A, et al.. Frequency of OBI among patients with autoimmune hepatitis. Asian Pac J Cancer Prev. 2020, 21:2555-9. 10.31557\/APJCP.2020.21.9.2555","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape S","year":"2022","unstructured":"Pape S, Snijders RJ, Gevers TJ, et al.. Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 2022, 76:841-9. 10.1016\/j.jhep.2021.12.041","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2013.09.005","article-title":"Evaluation of abnormal liver tests","volume":"98","author":"Woreta TA","year":"2014","unstructured":"Woreta TA, Alqahtani SA. Evaluation of abnormal liver tests. Med Clin North Am. 2014, 98:1-16. 10.1016\/j.mcna.2013.09.005","journal-title":"Med Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo RP","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015, 148:221-244.e3. 10.1053\/j.gastro.2014.10.038","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba R","year":"2017","unstructured":"Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017, 152:1297-309. 10.1053\/j.gastro.2017.02.009","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67:370-98. 10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-99. 10.1002\/hep.29800","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390341-the-effect-of-latent-hepatitis-b-infection-on-autoimmune-hepatitis-treatment-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:36:38Z","timestamp":1753814198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390341-the-effect-of-latent-hepatitis-b-infection-on-autoimmune-hepatitis-treatment-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.88997","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}